- Sep 18, 2022
NCT05463939: Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Myeloma
- Mar 1, 2022
NCT05218603: Bortezomib Plus Daratumumab (V-Dara) After Induction With VMP-Dara - NDMM -TIE Myeloma
- Dec 16, 2021
NCT05160584: A Study of Real-Life Current Standards of Care in Participants With RRMM (MoMMent)
- Dec 10, 2021
NCT05053607: Real World Insights During Treatment for Relapsed/Refractory Myeloma With Isatuximab
- Jun 29, 2021
NCT04770402: Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma Patients
- Jun 23, 2021
NCT04937777: EMN 23 - Study on the Management & Outcome of Systemic AL Amyloidosis in Europe
- Jun 17, 2021
NCT04721002: Evaluate t(11;14) Status & BCL2 Expression in Adult Participants With MM (MEDICI)
- Jun 2, 2021
NCT04827563: Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib
- Dec 18, 2020
NCT04458831: A Non-interventional, Multinational, Observational study With Isatuximab in RRMM
- Dec 10, 2020
The clonoSEQ® Watch Registry
- Dec 13, 2019
NCT04108624: Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patients
- Dec 4, 2018
NCT03763370: Expanded Access Request Program for Belantamab Mafodotin (GSK2857916) in Myeloma
- Dec 22, 2017
Post-transplant consolidation plus lenalidomide maintenance vs lenalidomide maintenance alone
- Dec 15, 2017
NCT03106324: Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma -TNE
- Dec 2, 2017
NCT03327597 : Iceland Screens, Treats or Prevents Multiple Myeloma (iStopMM)
- Dec 9, 2016
NCT02884102: MMRF Molecular Profiling Protocol - Multiple Myeloma Research Foundation
- Dec 16, 2011
NCT01410500: Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With RRMM Myeloma
- Dec 9, 2011
NCT01454297: MMRF CoMMpass Study in Newly Diagnosed Multiple Myeloma - (CoMMpass)
- Dec 16, 2009
A Meta-Analysis: Tandem Vs Single Autologous Hematopoietic Cell Transplantation Myeloma - JNCI 2009